Cannabis Science (cbis) 469% The Company Specializes In The Development Of Cannabinoid-based Medications And Recently Announced A Collaborative Research Agreement With Dana Farber/harvard Cancer Center.

Marijuana IPO Our flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM. In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldnt you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80. Vitality Biopharma (VBIO) 361% A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders. Cannabis Science (CBIS) 469% The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin Medical marijuana stocks cancers, HIV/AIDS, and neurological conditions.

To read more visit http://marijuanastocks.com/marijuana-stocks-inauguration-day-the-trump-bump/

Posted in: Investing

Comments are closed.